Exploring kidney dialysis costs in the United States: a scoping review
CONCLUSIONS: These findings indicate that prevention of or delay in progression to ESRD could have considerable cost savings for Medicare and private payers, particularly in patients with high-risk conditions such as type 2 diabetes. More efficient use of resources is needed, including low-cost medication, to improve clinical outcomes and lower overall costs, especially in high-risk groups. Widening access to PD where it is safe and appropriate may help to reduce dialysis costs.PMID:38605648 | DOI:10.1080/13696998.2024.2342210
Source: Journal of Medical Economics - Category: Health Management Authors: Fiona Stewart Kristin Kistler Yuxian Du Rakesh R Singh Bonnie B Dean Sheldon X Kong Source Type: research
More News: Diabetes | Diabetes Type 2 | Dialysis | Economics | Endocrinology | Health Management | Hemodialysis | Hepatitis | Hepatitis C | Insurance | Insurers | Medicare | Peritoneal Dialysis | Study | Urology & Nephrology | USA Health